This 1999 prospective study from Armstrong et al. asks a focused biomechanical question: how much does percutaneous Achilles tendon lengthening (TAL) reduce peak plantar forefoot pressure in diabetic patients with prior neuropathic ulceration and clinical equinus deformity? Ten patients underwent gait analysis with a validated force-plate system immediately before and eight weeks after percutaneous TAL.
When you encounter a diabetic patient with peripheral neuropathy, forefoot ulcer history, and limited ankle dorsiflexion (equinus), percutaneous TAL should be on your surgical planning radar — this study established that correcting equinus reduces peak forefoot pressure below the threshold most strongly associated with ulceration.
Postoperatively, protect the repair with a weight-bearing below-knee cast for 6 weeks before transitioning to therapeutic footwear.
This 1999 prospective study from Armstrong et al. asks a focused biomechanical question: how much does percutaneous Achilles tendon lengthening (TAL) reduce peak plantar forefoot pressure in diabetic patients with prior neuropathic ulceration and clinical equinus deformity? Ten patients underwent gait analysis with a validated force-plate system immediately before and eight weeks after percutaneous TAL.
When you encounter a diabetic patient with peripheral neuropathy, forefoot ulcer history, and limited ankle dorsiflexion (equinus), percutaneous TAL should be on your surgical planning radar — this study established that correcting equinus reduces peak forefoot pressure below the threshold most strongly associated with ulceration.
Postoperatively, protect the repair with a weight-bearing below-knee cast for 6 weeks before transitioning to therapeutic footwear.